HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Medical

This article was originally published in The Gray Sheet

Executive Summary

Firm receives IDE approval from FDA to begin its Post AV Node Ablation Evaluation (PAVE) clinical trial for patients with chronic atrial fibrillation receiving an 'ablate and pace' procedure, St. Jude announces Aug. 22. The 600-patient, 65-center study will compare the effects of left ventricular or biventricular pacing with right ventricular pacing, which is the current standard of care. The study, which will use St. Jude's Frontier stimulation device and Aescula left heart lead, will randomize patients to one of three arms. Patients in the left ventricular arm will also receive a right ventricular lead to provide backup right ventricular pacing. Endpoints include the six-minute walk test and quality of life assessment
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel